MARKET

OTIC

OTIC

Otonomy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.790
+0.120
+3.27%
Closed 16:00 10/23 EDT
OPEN
3.680
PREV CLOSE
3.670
HIGH
3.810
LOW
3.670
VOLUME
91.62K
TURNOVER
--
52 WEEK HIGH
4.890
52 WEEK LOW
1.530
MARKET CAP
182.78M
P/E (TTM)
-2.6424
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Bristol Myers Squibb's Newest Immunotherapy Approval, And Other News: The Good, Bad And Ugly Of Biopharma
Bristol Myers Squibb receives FDA approval for immunotherapy combo.iBio inks deal with Safi Biosolutions for harnessing FastPharming System.Otonomy reports completing patient recruitment for Otividex trial.
Seekingalpha · 10/05 06:59
Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX® in Ménières Disease
SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the completion of patient enrollment in the Phase 3 clinical trial of OTIVIDEX in Ménière’s disease. A total
GlobeNewswire · 10/02 12:30
Otonomy completes enrollment in pivotal study of Otvidex in inner ear disorder
Otonomy (OTIC) has completed the enrollment of 142 subjects in a Phase 3 clinical trial evaluating Otividex, a sustained-exposure formulation of the corticosteroid dexamethasone injected through the eardrum, in patients
Seekingalpha · 10/02 11:53
Otonomy Canada Launches Matchmaking Platform For Buyers And Sellers Of Small Businesses
https://www.newswire.ca/news-releases/otonomy-canada-launches-matchmaking-platform-for-buyers-and-sellers-of-small-businesses-881209150.html
Benzinga · 09/30 13:10
Otonomy (OTIC) Investor Presentation - Slideshow
The following slide deck was published by Otonomy, Inc. in conjunction with this event.
Seekingalpha · 09/18 17:38
What Kind Of Shareholders Hold The Majority In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?
If you want to know who really controls Otonomy, Inc. (NASDAQ:OTIC), then you'll have to look at the makeup of its...
Simply Wall St. · 09/15 13:52
Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
Zacks · 09/10 13:41
Otonomy to Participate in Four Upcoming Investor Conferences
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in four upcoming virtual investor conferences. * Citi’s 15th Annual
GlobeNewswire · 09/02 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OTIC. Analyze the recent business situations of Otonomy through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OTIC stock price target is 9.40 with a high estimate of 11.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 20.03M
% Owned: 41.53%
Shares Outstanding: 48.23M
TypeInstitutionsShares
Increased
18
1.82M
New
8
-45.69K
Decreased
19
813.07K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.58%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Independent Director
Jay Lichter
President/Chief Executive Officer/Director
David Weber
Chief Financial Officer
Paul Cayer
Chief Technology Officer
Robert Savel
Independent Director
James Breitmeyer
Independent Director
Vickie Capps
Independent Director
Ciara Kennedy
Independent Director
Iain McGill
Independent Director
Theodore Schroeder
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OTIC
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Otonomy Inc stock information, including NASDAQ:OTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTIC stock methods without spending real money on the virtual paper trading platform.